|
Toggle Summary
August 1, 2023
|
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
BURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the second
|
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
|
|
Toggle Summary
June 28, 2023
|
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
BURLINGTON, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it has agreed to sell an aggregate of 1,425,000 shares
|
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
|
|
Toggle Summary
May 15, 2023
|
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
Company to host conference call today at 8:30 a.m. ET BURLINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported
|
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
|
|
Toggle Summary
May 10, 2023
|
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
FDA confirms acceptance of the filing of the NDA for roluperidone Application has been granted a standard review FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of February 26, 2024 BURLINGTON, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc.
|
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
|
|
Toggle Summary
May 8, 2023
|
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
Management to Host Conference Call BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will
|
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
|
|
Toggle Summary
May 1, 2023
|
Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
FDA grants appeal and files NDA BURLINGTON, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that the U.S.
|
Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
|
|
Toggle Summary
March 8, 2023
|
Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates
Company to Host Conference Call Today at 8:30 a.m. ET BURLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported
|
Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates
|
|
Toggle Summary
March 1, 2023
|
Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023
Management to Host Conference Call BURLINGTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will
|
Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023
|
|
Toggle Summary
December 28, 2022
|
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
BURLINGTON, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that, following the Type A meeting held on November
|
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
|
|
Toggle Summary
November 9, 2022
|
Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates
Company To Host Live Webcast Today at 8:30 a.m. ET BURLINGTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key
|
Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates
|
